Gerard Barron

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Bruce Cree, Jeffrey L. Bennett, Ho Jin Kim et al. · The Lancet · 2019 · 717 citations

Medicine, Neurology, Pharmacotherapy +4

Development and application of polymerase chain reaction (PCR) tests for the detection of subgroup J avian leukosis virus

L. M. Smith, Susan Brown, K. Howes et al. · Virus Research · 1998 · 177 citations

Veterinary Medicine, Infectious Diseases, Molecular Biology +14

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 142 citations · Full text

Life Sciences, Immunology, Neurology +17

Neuromyelitis optica spectrum disorder

Janine B. Beekman, Aysha Keisler, Omar Pedraza et al. · Neurology Neuroimmunology & Neuroinflammation · 2019 · 131 citations · Full text

Medicine, Neurology, Health Psychology +16

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

Bruce Cree, Jeffrey L. Bennett, Mark Sheehan et al. · Multiple Sclerosis Journal · 2015 · 71 citations · Full text

Medicine, Neurology, Neuroscience +15